| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
MC1568 is a hydroxyamide-based inhibitor of class II histone deacetylase (HDAC) such as HDAC4/5/6/7/9 (IIa) and HDAC6/10 (IIb) with potential antiviral activity. It blocks the influenza A virus from multiplying.
| Targets |
HD1-A ( IC50 = 100 nM ); HD1-B ( IC50 = 3.4 μM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
Scintillation counting is used to measure the amount of tritiated acetic acid that the enzyme extracts from the substrate. Triple determinations produce IC50 values. Ten microliters of total [3H]acetate-prelabeled chicken reticulocyte histones (2 mg/mL) are incubated for 30 minutes with a 50 μL sample of maize enzyme at 30 °C. To halt the reaction, add 800 μL of ethyl acetate and 50 μL of 1 M HCl/0.4 M acetate. A 600 μL aliquot of the upper phase is centrifuged at 1×104 g for 5 minutes, and its radioactivity is measured in 3 mL of liquid scintillation cocktail. Active ingredients are further diluted after MC1568 is tested at a starting concentration of 40 μM. The reference compounds are NaB, VPA, TSA, SAHA, 85 TPX, HC-toxin, and tubacin; the negative controls are blank solvents.
|
|
| Cell Assay |
Using a combination of insulin, dexamethasone, and isobutylmethylxanthine, 3T3-L1 cells are grown and differentiated. During the eight-day differentiation period starting on the second day after confluence, the 3T3-L1 cells are stimulated by: (1) No induction: the cells are cultured with DMSO or MC1568 at post-confluence and for the entire 8-day differentiation period. (2) Troglitazone: the cells are induced with 5 μM troglitazone, MC1568, or both at post-confluence and for the duration of the 8-day differentiation period. (3) Rosiglitazone: the cells are cultured with 1 μM rosiglitazone and either DMSO or MC1568 at post-confluence and for the duration of the 8-day differentiation period. (4) Dexamethasone and rosiglitazone: the cells were given 390 ng/mL dexamethasone and 1 μM rosiglitazone at post-confluence. The cells are induced with 1 μM rosiglitazone and either DMSO or MC1568 for the duration of the 8-day differentiation period. Every two days, all media are refreshed.
|
|
| Animal Protocol |
|
|
| References | ||
| Additional Infomation |
3-[4-[3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methyl-2-pyrrolyl]-N-hydroxy-2-propenamide is a carbonyl compound.
|
| Molecular Formula |
C17H15FN2O3
|
|
|---|---|---|
| Molecular Weight |
314.31
|
|
| Exact Mass |
314.106
|
|
| Elemental Analysis |
C, 64.96; H, 4.81; F, 6.04; N, 8.91; O, 15.27
|
|
| CAS # |
852475-26-4
|
|
| Related CAS # |
|
|
| PubChem CID |
11381449
|
|
| Appearance |
Pink to red solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Index of Refraction |
1.572
|
|
| LogP |
2.91
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
492
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
C(/C1=CC=C(/C=C/C(=O)NO)N1C)=C\C(C1C=CC=C(F)C=1)=O
|
|
| InChi Key |
QRDAPCMJAOQZSU-KQQUZDAGSA-N
|
|
| InChi Code |
InChI=1S/C17H15FN2O3/c1-20-11-12(9-15(20)6-8-17(22)19-23)5-7-16(21)13-3-2-4-14(18)10-13/h2-11,23H,1H3,(H,19,22)/b7-5+,8-6+
|
|
| Chemical Name |
(E)-3-[4-[(E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-N-hydroxyprop-2-enamide
|
|
| Synonyms |
MC1568; MC 1568; MC-1568
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (3.18 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.5% CMC: 5mg/mL View More
Solubility in Formulation 3: 2.5 mg/mL (7.95 mM) in 17% Polyethylene glycol 12-hydroxystearate in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1816 mL | 15.9079 mL | 31.8157 mL | |
| 5 mM | 0.6363 mL | 3.1816 mL | 6.3631 mL | |
| 10 mM | 0.3182 mL | 1.5908 mL | 3.1816 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
